期刊文献+

液相色谱-质谱法分析磷酸芦可替尼中强制降解后的产物 被引量:2

Identification of forced degradation compounds in ruxolitinib phosphate by liquid chromatography-mass spectrometry
原文传递
导出
摘要 目的采用液相色谱-质谱法(LC-MS)联用对磷酸芦可替尼强制降解后的产物进行色谱分离,并对其结构进行鉴定。方法对各降解杂质进行分离的液相色谱法以YMC Triart C_(18)(4.6 mm×150 mm,3μm)为色谱柱;以甲醇和水为流动相,梯度洗脱;检测波长230 nm。同时采用LC-MS法,运用UPLC串联6540B Q-TOF仪器对主要的降解产物进行初步定性研究。结果对磷酸芦可替尼各降解产物进行了有效分离,并初步鉴定出11个主要降解产物的结构。结论本法可用于磷酸芦可替尼有关物质的检测,为其药品质量的控制提供了参考。 Objective To separate and identify the forced degradation products of ruxolitnib phosphate by liquid chromatography-mass spectrometry(LC-MS).Methods The separation was performed on a YMC Triart C_(18) column(4.6 mm×150 mm,3μm)by gradient elution with methanol water buffer.The UV detection wavelength was 230 nm.The main degradation products were qualitatively studied by UPLC in series with 6540b Q-TOF.Results The degradation products of ruxolitnib phosphate were effectively separated and 11 degradation products were preliminarily identified.Conclusion The method can be used for the determination of related substances in ruxolitnib phosphate,which can provide basis for the drugs quality control.
作者 刘发贵 孙丽霞 李敏 刘思光 李铁健 张贵民 LIU Fa-gui;SUN Li-xia;LI Min;LIU Si-guang;LI Tie-jian;ZHANG Gui-min(Shandong New Times Pharmaceutical Co.Ltd.,Linyi Shandong 273400;Lunan Pharmaceutical Group Co.Ltd.,Linyi Shandong 276002)
出处 《中南药学》 CAS 2022年第4期893-897,共5页 Central South Pharmacy
关键词 液相色谱-质谱法 磷酸芦可替尼 有关物质 降解产物 LC-MS ruxolitinib phosphate related substance degradation product
  • 相关文献

参考文献9

二级参考文献47

  • 1高磊,石嫱.HPLC法测定萘普生有关物质[J].中国药品标准,2005,6(6):17-19. 被引量:2
  • 2Gregory SA, Mesa RA, Hoffman R, et al. Clinical and laboratory features of myelofibrosis and limitations of current therapies [ J ]. Clin Adv Hematol Onco1,2011 ;9 ( Suppl. 22 ) : S1 - S16.
  • 3Cervantes F, Pereira A. Advances in the understanding and management of primary myelofibrosis [ J ]. Curr Opin Oncol, 2011 ; 23 : 665 - 671.
  • 4Baxter EJ,Scott LM, Campbell PJ,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloprollferative disorders [ J ]. Lancet, 2005 ; 365 : 1054 - 1061.
  • 5Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL) -8, IL-2R, IL - 12, and IL - 15 levels are independently prognostic in primary myelofibrosis : a comprehensive cytokine profi- ling study [ J ]. J Clin Oncol,2011 ; 29 : 1356 - 1363.
  • 6Campbell PJ, Griesshammer M, Dghner K,et al. The V617Fmutation in JAK2 is associated with poorer survival in idiopathic myeloibrosis[J]. Blood, 2006; 107:2098 - 2100.
  • 7Panteli KE, Hatzimiehael EC, Bouranta PK,et al. Serum interleu- kin (IL) - 1, IL - 2, sIL - 2Ra, IL - 6 and thrombopoietin levels in patients with chronic myeloproliferative diseases [ J ]. Br J Haema- to1,2005 ; 130:709 - 715.
  • 8Shi JG, Chen X, McGee RF,et al. The Pharmacokinetics, phanna- codynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers[ J]. J Clin Pharmacol, 2011 ;51:1644 -1654.
  • 9Shilling AD, Nedza FM, Emm T,et al. Metabolism, excretion, and pharmacokinetics of [ 14C] -INCB018424, a selective Janus tyro- sine kinase 1/2 inhibitor, in humans[ J]. Drttg Metab Dispos ,2010 ; 38:2023 - 2031.
  • 10Verstovsek S, Kantarjian H, Mesa RA,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis[J]. N Engl J Med,2010 ;363 : 1117 - 1127.

共引文献17

同被引文献12

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部